Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development

Area of Science:

• Neuroscience
• Developmental Biology
• Epileptology

Background:

• Malformations of cortical development are a leading cause of pediatric epileptic encephalopathies and drug-resistant epilepsy.
• Current epilepsy treatments are frequently ineffective, necessitating novel therapeutic targets for cortical malformation-associated epilepsies.

Purpose of the Study:

• To investigate the role of the mechanistic/mammalian target of rapamycin (mTOR) pathway in epileptogenesis.
• To evaluate mTOR inhibitors as potential antiseizure and antiepileptogenic therapies for pediatric cortical malformation-related epilepsies.

Main Methods:

• Review of genetic studies linking mTOR pathway genes to cortical malformations.
• Analysis of preclinical data from mouse models (e.g., tuberous sclerosis complex).
• Examination of ongoing clinical trials for mTOR inhibitors in drug-resistant epilepsy.

Main Results:

• The mTOR pathway is implicated in the cellular and molecular mechanisms of epileptogenesis across various focal cortical malformations.
• mTOR inhibitors have demonstrated efficacy in preventing epilepsy and related pathogenic mechanisms in mouse models.
• Genetic studies have connected mTOR pathway gene mutations to conditions like focal cortical dysplasia and hemimegalencephaly.

Conclusions:

• mTOR inhibitors are promising therapeutic candidates for epilepsy associated with a spectrum of cortical malformations.
• Targeting the mTOR pathway offers a novel strategy for antiseizure and antiepileptogenic treatments in pediatric epilepsy.